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ABSTRACT: Beta-defensins are a family of multifunctional
genes with roles in defense against pathogens, reproduc-
tion, and pigmentation. In humans, six beta-defensin genes
are clustered in a repeated region which is copy-number
variable (CNV) as a block, with a diploid copy number
between 1 and 12. The role in host defense makes the
evolutionary history of this CNV particularly interesting,
because morbidity due to infectious disease is likely to have
been an important selective force in human evolution, and
to have varied between geographical locations. Here, we
show CNVof the beta-defensin region in chimpanzees, and
identify a beta-defensin block in the human lineage that
contains rapidly evolving noncoding regulatory sequences.
We also show that variation at one of these rapidly evolving
sequences affects expression levels and cytokine respon-
siveness of DEFB103, a key inhibitor of influenza virus
fusion at the cell surface. A worldwide analysis of beta-
defensin CNV in 67 populations shows an unusually high
frequency of high-DEFB103-expressing copies in East
Asia, the geographical origin of historical and modern
influenza epidemics, possibly as a result of selection for
increased resistance to influenza in this region.
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Introduction
Copy number variation (CNV) is an important source of human
genetic diversity, and can result in phenotypic diversity and
different susceptibilities to disease [Conrad et al., 2009; Sudmant
et al., 2010; Wain et al., 2009]. Most studies have been based either
on genomewide surveys where CNV detection and calling is heavily
biased toward copy number changes that cause a large change in
dosage, such as deletions, or on locus-specific studies on limited
sample sets with error-prone calling of diploid copy number.
Genome-wide analyses suggest overall reduced purifying selection
on gene copy number in Drosophila melanogaster [Dopman and
Hartl, 2007; Emerson et al., 2008], and in humans [Nguyen et al.,
2008], yet analyses of individual CNVs have suggested neutral
evolution, for example, at those containing chemosensory genes
[Nozawa et al., 2007; Young et al., 2008]. There is also some
evidence for positive selection acting on certain CNVs in humans,
such as the amylase locus where populations with a higher average
copy number have a history of starch-rich diets [Perry et al., 2007],
and the UGT2B17 gene (MIM] 601903), which encodes a minor
histocompatibility antigen [Xue et al., 2008].
Beta-defensins are a family of proteins characterized by a
conserved 6-cysteine motif, which results in a characteristic
arrangement of three disulfide bridges in the mature protein
[Ganz, 2003; Pazgier et al., 2006]. Six members of the beta-
defensin family at chromosome 8p23.1 (DEFB4, DEFB103,
DEFB104, DEFB105, DEFB106, DEFB107) are annotated as a
block that is copy number variable, with diploid copy numbers
between 1 and 12 [Groth et al., 2008; Hollox et al., 2003, 2005,
2008a]. We refer to this copy number variable block as the beta-
defensin CNV. Three other beta-defensin genes (DEFB1,
DEFB108, and DEFB109) are also annotated to this region but
lie outside the beta-defensin CNV; DEFB1 is not copy number
variable, whereas DEFB108 and DEFB109 show very complex
structural variation within olfactory receptor regions, with an
unclear relationship to the beta-defensin CNV. All these beta-
defensin genes encode short cationic peptides between 2 and
6kDa in size and variously expressed in epithelia and the testis.
DEFB4 (MIM] 602215) and DEFB103 (MIM] 606611) are the
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ties and pro- and anti-inflammatory signaling capacity through
interactions with several receptors, including CCR6 and MCR1
[Candille et al., 2007; Feng et al., 2006; Harder et al., 2001;
Niyonsaba et al., 2004; Schibli et al., 2002; Semple et al., 2010;
Yang et al., 1999].
The beta-defensin CNV is at least 250kb in size and present in
multiple copies at two loci that are separated by  5Mb of single
copy sequence, which itself is polymorphically inverted [Abu
Bakar et al., 2009; Giglio et al., 2001; Sugawara et al., 2003].
Increased copy number is correlated with increased levels of
hBD-2 peptide (encoded by the DEFB4 gene) and has been
associated with an increased risk of developing the inflammatory
skin disease psoriasis [Hollox et al., 2008c; Jansen et al., 2009].
This variation accounts for about 5% of the total sibling
recurrence risk of this disease, equivalent to the amount of sibling
recurrence risk identified in the first generation of genomewide
association studies [Roberson and Bowcock, 2010]. Initial studies
of association of beta-defensin CNV with Crohn’s disease have not
been substantiated in larger studies, and demonstrate the
importance of accurate copy number typing in association studies
[Aldhous et al., 2010; Bentley et al., 2009; Fellermann et al., 2006].
The beta-defensin CNV has a high copy number mutation rate of
around 0.7% per generation, caused mostly by allelic recombina-
tion in the 5Mb between the two CNV loci leading to the
inheritance of novel combinations of blocks [Abu Bakar et al.,
2009]. The beta-defensin genes in this CNV do not show strong
evidence of positive selection at the amino acid level [Hollox and
Armour, 2008], but such selection would be distinct from
selection for gene dosage variation, and this remains unstudied.
Indeed, it could be argued that selection for gene dosage changes
would prevent coding sequence divergence between paralogues, as
the favorable trait is increased or decreased levels of the same
protein [Kondrashov et al., 2002; Schuster-Bockler et al., 2010].
Here, we investigate the recent evolution of the beta-defensin
CNV by showing beta-defensin copy number variation in
chimpanzees, identifying two types of beta-defensin CNV block by
comparative sequence analysis, and showing that regulatory
sequences have rapidly diverged. We analyse the frequency of the
two types of beta-defensin CNV block in 67 populations from across
the globe, and discuss possible interpretations of the pattern seen.
Materials and Methods
Samples
Unrelated human DNA samples were from the standardized
subset of 1,056 individuals from the HGDP-CEPH panel [Cann
et al., 2002; Rosenberg, 2006], the HapMap phase I panel (45
CHB—Chinese from Beijing, 45 JPT—Japanese from Tokyo, 60
CEU—European Americans from Utah, 60 YRI—Yoruba from
Nigeria), the Health Protection Agency or directly extracted from
human peripheral blood (Supp. Table S1). Pan troglodytes
troglodytes DNA samples were from mouthswabs self-adminis-
tered by animals, and extracted using a column-based method,
according to the manufacturer’s instructions (Isohelix, Maidstone,
UK). Pan troglodytes verus DNA samples were from lymphoblas-
toid cell lines made available by the INPRIMAT consortium.
Human DNA samples used in this study were either from
publically available cell lines maintained by Coriell Cell Reposi-
tories or the Health Protection Agency (UK) or from peripheral
blood collected under appropriate local ethical consent.
Copy Number Typing in Humans
Beta-defensin copy number was directly determined using a
triplex paralogue ratio test (PRT), as previously published
[Aldhous et al., 2010] (Supp. Fig. S1). The quality of copy
number calling can be judged qualitatively by examining
histograms of raw copy number calls because, given the
expectation that copy numbers are integers, values will cluster
about those integer values. The raw data, displayed as a mean of
the triplex assay, are shown on a histogram (Supp. Fig. S2a and b),
and show clear clustering around integer values. The three
independent measures of copy number produced by this test were
used to infer the most likely copy number for each sample using a
maximum-likelihood approach [Aldhous et al., 2010; Hollox et al.,
2008b]. This approach also allows, for each sample, a statistical
estimate of the confidence in the calling of that particular copy
number compared to all other potential copy numbers. Each copy
number call was assigned a P-value, representing the likelihood of
that copy number call compared to all other copy number calls,
with 95.5% of samples having copy number calls with Po0.05.
The copy number of clade II was determined using polymerase
chain reaction (PCR) amplification followed by restriction
enzyme digestion and quantification of the two digested products.
Primers flanking rs2737902 (50-CCCAGAACTAACACACCCTTG-30
and 50-CTCTTGGCTCAGGAGCATTC-30) were used to amplify a
PCR product from 10ng genomic DNA, following the standard
Kapa Taq DNA polymerase reaction conditions (Kapa Biosystems)
and cycling conditions of at 981C 2min, followed by 27 cycles of
981C 20sec, 631C 60sec, 701C 60sec, and a final extension cycle of
701C for 10min. A total of 2ml of PCR product was added to a
restriction enzyme digestion mix containing 1 unit of BsrI( N e w
England Biolabs, Beverly, MA), incubated at 371C for at least 4hr
and then electrophoresed; fragments were quantified using an
ABI3130 genetic analyzer and GeneMapper software (Applied
Biosystems, Bedford, MA). Known clade II copy number controls
were included in every experiment, and used to calibrate the raw
ratio results, to minimize the effect of heteroduplex formation,
which consistently underestimates the amount of cut fragment by
being refractory to restriction enzyme digestion. Copy number of
clade II was determined using a maximum-likelihood approach
given the known total beta-defensin copy number and the ratio of
cut:uncut fragments.
Copy Number Typing in Chimpanzees
Two approaches were used to determine the copy number and
size of the variable beta-defensin region in the chimpanzees (Supp.
Fig. S1). The HSPD21 PRT assay described previously [Aldhous
et al., 2010] was predicted to work with chimpanzee DNA, based
on sequence comparison. In addition, analysis of the NCBI
sequence trace archive identified a chimpanzee-specific variable
short tandem repeat within the putative beta-defensin copy
number variable region (Supp. Fig. S3). The short tandem repeat
was amplified using final concentrations of 1mM of each primer
(50-FAM-GGCTCTCACTTGGTCTCTGG-30,5 0-GAGTGTTTGCT
GAGGCTTCC-30), 3mM of each dNTP, 1 Kappa HiFi buffer
(containing 2mM MgCl2), 0.2 units Kappa HiFi HotStart Taq
DNA Polymerase (Kappa Biosystems, Woburn, MA), and 10ng
genomic DNA in a final volume of 10ml. Thermal cycling was
performed on a Perkin-Elmer 9700 (Norwalk, CT), at 951C 2min,
followed by 30 cycles of 951C 30sec, 581C 30sec, 701C 30sec. Of
the 15 samples typed using both assays, 12 reported copy number
variation in agreement with each other, suggesting that the region
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bloc, at least on most chromosomes. We cannot rule out
heterogeneity in copy number of some blocks, but this hetero-
geneity was seen on samples showing wide 95% confidence
intervals for the PRT, and suggests that PRT assays thoroughly
optimized for the chimpanzee genome are likely to show smaller
confidence intervals.
Paralogue-Specific PCR and Sequencing
Potential nucleotide sites variable between paralogues in
chimpanzees were identified by searching the Trace Archive at
NCBI. Following identification of a FokI RFLP near DEFB4 that
showed a very high rate of apparent heterozygosity in our
chimpanzee samples (indicating that it was likely a variant
distinguishing paralogues), a paralogue-specific PCR was designed
to specifically amplify two copies of each paralogue from four
copy Pan troglodytes verus samples. The paralogue specific primer
was 50-TGCTTTGCTCCTCCTGCA-30 or 50-TGCTTTGCTCCTC
CTGCG-30, with a common reverse primer 50-AGTTGCTCACA
TATGAGAGC-30. Amplification used Kapa HiFi HotStart Taq
DNA polymerase according to the manufacturer’s instructions.
The PCR products were directly sequenced and, because no
sequence showed apparent heterozygosity at more than one
position, sequence haplotypes could be assigned.
Statistical Analysis
Summary statistic calculations and analysis of variance were
performed using Microsoft Excel. Principal component analysis
and biplot generation was performed using R, on 54 populations
where the number of samples was greater than 12. Mapping was
performed using Surfer 8.0 (Golden Software, Golden, CO), FST
permutation tests performed using Arlequin [Excoffier et al.,
2005], and randomization Monte Carlo simulation tests per-
formed using macros written using Visual Basic for Excel. Sliding
window nucleotide divergence analysis was performed using
DnaSP 4.0 [Rozas et al., 2003], with bootstrap tests for
heterogeneity performed using Excel. Tree and network generation
was performed using Splitstree 4.0 [Huson and Bryant, 2006].
The genome-wide scan for single nucleotide polymorphisms
SNPs associating with beta-defensin copy number and previously
published RHD copy number [McCarroll et al., 2008] was
performed on the founder CEU individuals (n560, 2.3 million
SNPs), founder YRI individuals (n560, 2.6 million SNPs), and
unrelated JPT/CHB samples (n590, 4 million SNPs) in PLINK
1.07 by linear regression under an additive model [Purcell et al.,
2007]. P-Values were calculated in PLINK 1.07 by the Wald test
and adjusted for multiple testing by a Bonferroni correction.
Whole-genome SNP genotypes were downloaded from HapMap
(release 23) and regional SNP association plots were generated.
Pairwise LD (r
2) between the selected ‘‘lead’’ SNP (red diamond)
and neighboring HapMap SNPs were calculated using ssSNPer
with the method described (http://gump.qimr.edu.au/general/
daleN/ssSNPer/). CNV positions were taken from published data
[Conrad et al., 2009], and all genome coordinates were based on
hg18 (NCBI Build 36).
Reporter Constructs and Transfection of Cell Lines
The pGL-promoter vector (Promega, Madison, WI) harbors the
SV40 promoter that was excised using BglII and HindIII
restriction enzymes (New England Biolabs). A 1.9-kb region of
the DEFB103 promoter region was amplified from BAC DNA
clones H292 SCb-497j4 (clade II sequence, accession AF202031.5),
RP11-1195F20 (clade IB sequence, accession AC130365.5), and
RP11-287P18 (clade IA sequence, accession AC130360.4) (BAC-
PAC Resources Center) by PCR using primers containing BglII/
HindIII restriction sites (generated using primers 50-GTCAA
GATCTCAGCACCCATCCCACCCAC-30,5 0-GTCAAAGCTTATG
CTAGGCTTCACCCCAC-30) and cloned into the digested pGL3
vector. Clones containing inserts were characterized by capillary
sequencing using the vector specific primers RVprimer3 and
GLprimer2. The pGL3-Basic vector and pGL-promoter vector
were used as negative and positive controls, respectively.
HaCaT (program U-020) cell lines were transfected by
nucleofection using the Ingenio
TM Electroporation Kit for
Lonza-amaxa Nucleofector devices according to the manufac-
turer’s protocol (Mirus, Madison WI). Briefly, 1 10
6 cells were
cotransfected with 3mg of the pGL3 plasmids and 300ng of the
pRL-TK Vector. Transfected cells were either unstimulated or
cultured in media (DMEM supplemented with 10% fetal calf
serum [FCS]) containing 100ng/ml IFN-g or 10mg/ml lipopoly-
saccharide. After 24hr the cells were washed in phosphate-
buffered saline, lysed, and harvested by using 500ml of Glo lysis
buffer (Promega) per well. Firefly luciferase activity from the
pGL3 reporter vectors and Renilla luciferase activity were
determined using the Dual-Glo
s Luciferase Assay System
(Promega) according to the manufacturer’s instructions. Lucifer-
ase values were recorded on a FLUOstar Omega microplate reader.
The experiment was performed on at least three separate
occasions, each time in triplicate, with the data representing a
total of at least nine separate measurements. Promoter activity was
normalized to the activity of the internal Renilla luciferase control.
Results
To investigate the evolutionary history of the complex beta-
defensin CNV, we compared this region in humans and
chimpanzees. In chimpanzees, there is some evidence from
array-CGH studies that the orthologous region shows CNV
[Marques-Bonet et al., 2009; Perry et al., 2008], but the size of the
array-CGH probes and the uncertainty, in paralogous regions, of
the genome assembly prompted us to examine the locus in more
detail. We developed a combined assay for analysis of chimpanzee
beta-defensin copy number using both the PRT [Armour et al.,
2007], which by comparing orthologous sequences was predicted
to work on chimpanzee DNA, and a short tandem repeat assay
within an intron of the SPAG11 gene. Copy numbers of 4, 5, and 6
were observed, confirming CNVof this region in chimpanzees in a
similar range to humans (Supp. Table S2), and highlighting the
fact that the one assembled copy of this region in the chimpanzee
genome assembly (CGSC 2.1/panTro2) is likely to be an error.
To examine the evolutionary relationship between chimpanzee
and human beta-defensin copies in more detail, we generated
sequences of a random 3.2-kb region near DEFB4 in chimpanzees,
present as a single copy per block, using paralogue-specific PCR
amplification from two chimpanzees (Pan troglodytes verus) each
carrying four blocks, and also identified seven different unique
orthologous sequences in humans from 12 previously sequenced
BACs. A network of these sequences was generated; one clade
containing nine human sequences (clade I) showed reticulations
reflecting a history of gene conversion and recombination between
these sequences (Fig. 1A). However, three sequences form a
separate clade (clade II) with no evidence of recombination with
clade I, at least in this 3.2kb region. The clade II sequences are all
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copy sequence represented in three independent BACs sampling
the same genomic region. The 3.2-kb DEFB4-linked region
sequences thus led to the identification of sequenced BACs
containing either clade I or II sequences that were used in
subsequent investigations.
We compared the similarity of the clade II sequence with the
two sequences representing clade I assembled in the human
reference genome (hg18) across 105kb of the beta-defensin block.
Using a sliding window approach, the frequency of nucleotide
differences between clade I and clade II was compared with the
frequency of nucleotide differences within clade I. This is
analogous to the widely used HKA test, which compares
between-species differences to within-species diversity [Hudson
et al., 1987]. Overall, the diversity between the clades was low
(around 0.3%), but the pattern of clade I–clade II divergence was
significantly heterogeneous across the region (Po2.2 10
 16,
runs test), with the top 5% of values clustering around, but not
within, the exons of particular genes (Fig. 1B). This suggests either
an unusually rapid sequence divergence, or absence of the
homogenizing effect of gene conversion, between clades in
potential regulatory regions. Importantly, there is only one
protein-coding nucleotide change between the assembled clade I
and clade II sequences (rs2740707 in SPAG11), suggesting that
differences in beta-defensin protein sequences between clade I and
clade II are not responsible for our observations.
The lack of coding variation between clades I and II, and the
sequence divergence between copies only at putative regulatory
regions suggests natural selection is acting on gene expression. To
test this, we analyzed the expression of the DEFB103 gene, which
encodes human beta-defensin 3 (hbd-3), a protein secreted by
epithelia with broad-spectrum antimicrobial and antinflammatory
activities, and which shows the strongest clade I–clade II
divergence immediately upstream of exon 1. A 1.9-kb section of
the immediate upstream region from two clade I BACs (clade IA
and IB, representing the two sequences assembled in the hg18
human genome assembly) and the same 1.9-kb region from a
clade II BAC were cloned into luciferase reporter vectors and
transiently transfected into the immortalized keratinocyte epithe-
lial cell line HaCat. The clade II sequence drove a twofold higher
constitutive expression level of the reporter gene compared to the
clade I sequences, demonstrating that sequence changes identified
are responsible for variation in gene expression (Fig. 2). Sequence
differences between the two clade I sequences also influence the
response to interferon-g, although there is no evidence that these
have been subject to natural selection. Because there are no
sequence changes that are unique to clade IB versus IA and II, the
variable response to interferon-g is likely to be an effect of more
than one sequence change.
We reasoned that if natural selection were acting on DEFB103
gene expression, we might expect to see population-specific copy
number distributions of clade I and clade II copy number.
Initially, we typed 2015 individuals from 68 worldwide popula-
tions for total diploid beta-defensin copy number using PRT, and
found diploid copy numbers between 1 and 9, with a modal copy
number of 4, consistent with previous studies [Groth et al., 2008;
Hollox et al., 2003, 2005] (Fig. 3A, Supp. Table S3). Nested
analysis of variance showed that 96% of the observed copy
Figure 1. Evolutionary analysis of assembled beta-defensin copy number blocks. A: Recombination network of DNA sequences from a 3.2-kb
region within the beta-defensin CNV block. The scale indicates number of nucleotide differences. B: Regions of the beta-defensin copy number
repeat showing unusually high divergence of clade II. Peaks indicate regions that showed a divergence/diversity ratio in the top 5%.
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between populations (P50.002) and 1.8% between continental
regions (P50.01). To dissect the variation between populations,
we plotted the first two principal components of the diploid copy
number frequencies for each population (Fig. 3A). Neither
regional grouping nor any pattern reflecting the range expansion
out of Africa around 60,000 years ago was found. Instead, most
populations cluster with no apparent geographical structure but
with several outliers: Bantu, Mbuti, Quechua, Karitiana, Pathan,
and Kalash (Fig. 3B). These appear to reflect a significantly
different frequency for a particular copy number diplotype, either
four-copy or six-copy, likely reflecting a real difference in two-
copy and three-copy allele frequencies (Table 1). This effect is
likely to be due to recent population processes such as genetic
drift, and the two populations showing the most significant
differences (Karitiana and Kalash) are known to be population
isolates that have experienced genetic bottlenecks. Natural
selection or genetic drift may be responsible for the pattern in
the other outlier populations; nevertheless, given the importance
of the beta-defensin genes in innate immunity, we speculate that
these differences may have an effect on the susceptibility of the
population to certain diseases.
To determine the copy number of clade II blocks, we typed the
rs2737902 multisite variant in the DEFB103 promoter on a subset of
samples (1,759 individuals, 67 populations). Its nonancestral type is
a marker of clade II and is predicted to generate a GATA-1 binding
site. Clade II block frequency, as a proportion of total copy number,
showed a cline with the highest frequency in East Asia and lowest
frequency in Africa (Table 2, Supp. Table S4, and Fig. 4). There was
no association with a particular beta-defensin copy number beyond
a positive correlation between clade II copy number and beta-
defensin total copy number simply due to increased sampling
(P50.3, w
2 test). Permutation tests confirm a significant difference
(Po0.02) in rs2737902 diplotype frequencies in East Asia compared
to other geographical regions, except Oceania. Because clade II
carries the derived sequence and clade I the ancestral, this
geographical pattern suggests that clade II rose to significant
frequencies recently after the out-of-Africa range expansion.
Discussion
We have identified two types of human beta-defensin CNV
block (clade I and II) that are distinguished by high sequence
divergence at noncoding regulatory regions. Previously, it has been
shown that the beta-defensin CNV is present at two loci (distal
and proximal) separated by  5Mb of single copy sequence [Abu
Bakar et al., 2009]. This suggests a potential association between
physical position and CNV block type. Testing this association is
challenging, because we only know the physical location of the
beta-defensin CNV blocks in two CEPH families. We tested one
family for CNV block type and did not find a perfect association
of clade I/clade II with CNV physical position. A subtler effect
cannot be ruled out—for example, clade II copies occurring
polymorphically only at the distal CNV location—but we do not
have enough samples of known physical CNV position to test this
thoroughly, as yet. Similarly, the relationship between type of
beta-defensin CNV block and polymorphic inversion awaits a
large cohort typed for the polymorphic inversion.
We show that clade II copies are at a significantly higher
frequency in East Asians compared to other populations. Could
this effect be due to hitchhiking of clade II sequences on
haplotypes carrying another beneficial allele? We found no
association genomewide of particular SNP alleles with total
beta-defensin copy number or clade II copy number (Supp.
Fig. S4a–d), suggesting that the beta-defensin CNV does not
affect, nor is affected by, evolutionary processes at other linked
loci by genetic hitchhiking effects. This observation, together with
the absence of a signal at the beta-defensin CNV of the Out-of-
Africa range expansion and a high copy number mutation rate of
0.7% [Abu Bakar et al., 2009], supports a model where signals of
population movement and linkage disequilibrium of copy number
with flanking SNPs are rapidly erased from beta-defensin CNV
diversity. It follows that any population-specific variation that we
see is a result of recent selective or demographic events.
Distinguishing effects of natural selection from genetic drift is
particularly challenging for complex regions because it is not
possible to compare the observed pattern of variation to a
predicted pattern based on the standard neutral model. Recent
work has begun to construct a framework for neutral modelling of
fixed duplicate genes [Innan and Kondrashov, 2010; Thornton,
2007], and polymorphically duplicated regions, but as yet more
complex CNV regions are not described. This may be a
consequence with the extra parameters required to model
variation, and the consequent loss of predictive power of such
models. The result is a lack of well-validated tools that allow us to
detect departures from a neutral model. However, based on the
neutral assumption that the different blocks are evolving at the
same rate between blocks and across the block, we used a HKA-
like test that tests for departures from an equal rate of sequence
divergence across the three different beta-defensin blocks, and a
runs test that tests for significant heterogeneity in the rate of
sequence divergence across the block.
Figure 2. Characterization of DEFB103 promoters from different
clades. Promoter efficiency of 1.9kb upstream region of DEFB103 in
HaCat keratinocyte epithelial cell lines, with pGL3 empty vector as
negative control, and pGL3 with SV40 enhancer as a positive control,
using a luciferase reporter gene assay. Three promoters, two from
clade I corresponding to the two sequences assembled in hg18 human
genome, and one from clade II, were tested under three conditions:
nonstimulated (NS), interferon-gamma stimulation (IFN-gamma) and
Escherichia coli lipopolysacharride stimulation (LPS). Statistically
significant differences in expression between clades are shown, after
correction for multiple comparisons (Po0.05, Po0.01).
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II sequence, that clade II encodes higher expression of DEFB103 in
epithelial cells, and that clade II is at highest frequency in East Asia
prompted us to look for a selective explanation for our observations.
hbd-3 protein acts against several microbes that colonize and infect
epithelia, including Staphylococcus aureus and Candida albicans
[Harder et al., 2001], and viruses such as HIV-1 [Sun et al., 2005].
Additionally, hbd-3 inhibits influenza viral fusion with epithelial
Figure 4. Global distribution map of clade II copy frequency. Frequency of clade II copies is shown as a contour map with frequency
intervals colored according to the legend on the right of the map, and sampling locations shown as crosses (see also Supp. Table S1).
Figure 3. Principal component analysis of global variation of beta-defensin diploid copy number. A: Frequency distribution of worldwide beta-
defensin copy number. B: Biplot of the first two principal components of beta-defensin copy number variation data, representing 76% of the total
variation in the dataset. Outlier populations are highlighted. C: Frequency distributions of beta-defesin copy number in outlier populations.











Sub-Saharan Africa 268 1,174 66 0.05
America 332 1,256 128 0.09
Central-South Asia 230 839 158 0.16
East Asia 515 1,676 458 0.21
Europe 206 769 132 0.15
Table 1. Outlier Populations in Copy Number Distribution
Population
Copy number
frequency difference Significance (P)
Karitiana 4 copy increase o0.0001
Kalash 6 copy increase 0.0024
Bantu 6 copy increase 0.0061
Quechua 4 copy decrease 0.0071
Pashan 4 copy increase 0.0086
Mbuti 6 copy increase 0.0271
Outliers were identified visually from principal component analysis (Fig. 3B) and
particular changes in copy number frequency identify. Significance was assessed by a
Monte Carlo randomization test against the null hypothesis that the difference is due
to random sampling from the larger continental population.
748 HUMAN MUTATION, Vol. 32, No. 7, 743–750, 2011cells by forming a protective barrier of immobilized surface proteins
[Leikina et al., 2005], so it is likely that higher constitutive
expression levels provide increased resistance to influenza infection.
Further functional experiments relating DEFB103 genomic variation
to hbd-3 expression levels on epithelia and variability to infection
are necessary to conclusively establish this link. Over the past 10,000
years East Asia has developed a characteristic agriculture, combining
dense human population settlements and intensive pig-rearing with
standing water for wildfowl. Because of this environment, the region
is regarded as the source of many historical influenza epidemics
[Wolfe et al., 2007]. Thus, it is likely that this region suffered an
extensive burden of influenza in the past, and this is a plausible
selective explanation for our observations. Both Karitiana and Surui
in South America show high frequencies of clade II copies, which
distinguishes them from the seven other Amerindian populations
studied, and could be due to genetic bottlenecks, recent influenza
mortality, or a combination of both.
Selection for a higher level of expression is consistent with the
lack of coding sequence divergence between paralogues, as the
selected trait is increased or decreased levels of the same protein.
In this region of the genome, CNVaffects gene dosage of all genes
in the block, whereas single nucleotide variation can affect the
expression of just one gene. Although both forms of variation are
present in the population, an increase of hbd-3 protein level may
have been most advantageous. Indeed, increased expression of the
other beta-defensin genes may even have been disadvantageous,
favoring the spread of a sequence variant that increases hbd3 levels
specifically. This model should prompt further studies on the
evolutionary and functional relevance of sequence variation
within CNV for the beta-defensin CNV [Groth et al., 2010; Huse
et al., 2008; Taudien et al., 2010], and for other CNV regions.
Selection on gene expression levels of CNV genes is consistent
both with the long-term maintenance of CNVand maintenance of
nucleotide variation within promoter regions.
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